Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. - Wikidata - awgldk - TriplyDB

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

http://www.wikidata.org/entity/Q35157425

about

Anti-angiogenic alternatives to VEGF blockade A lesson for cancer research: placental microarray gene analysis in preeclampsia The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells.Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth Positron emission tomography imaging of CD105 expression during tumor angiogenesis.Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study.Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer Receptor-targeted anticancer therapy.Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.The physiological role of endoglin in the cardiovascular system.Endoglin-targeted cancer therapy.Endoglin for tumor imaging and targeted cancer therapy.Endoglin for targeted cancer treatment.Tumor vascular homing endgolin-targeted radioimmunotherapy in hepatocellular carcinoma.(89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy.Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis.Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer.Tumor radiosensitization by gene therapy against endoglin.Tumor angiogenesis and anti-angiogenic gene therapy for cancer.

P2860

Q26775947-4C96673A-D8AE-4178-B802-85D7093DC9A7 Q26827543-AECF0C58-8EDE-41FB-84DF-1BC42FFF2BFC Q30582833-B50FF7B9-01DF-4F97-8133-3FD95DB27B74 Q33913556-921BC523-9D54-4CF4-806D-3E2D72E3CBCE Q33957962-312A3349-3AEF-4811-8B40-FCF69E1C4950 Q34170622-BB67480E-2689-430F-BD12-A3950FBEB6D1 Q34341837-EFAB1337-DAAE-43BC-B3E6-476E4AF24CC4 Q34540047-F83B889B-FECC-4510-89FA-37AEDF77000A Q34672107-41F1CE04-0E64-4323-B8BD-423823A2D19D Q35017120-EF07E995-A60E-4145-98A4-817D8AFFABA8 Q35158941-D7790B8E-7383-4B73-9CE7-0B9DF57FFFC5 Q35201283-2211713A-F937-41DB-9597-77FEB427F2AC Q35291271-9C888BF0-CF75-4C5F-9CA6-40CDE905EBF8 Q35314203-FBFA19CF-006D-40D5-8F70-DA6DE36359D3 Q35536671-EB15E349-66BB-4AB9-A5C0-C6A9C7C9FC08 Q35851032-AC06FBDD-E86C-4312-BDE8-7A9A8E4D4E61 Q36510958-6385F2F6-252C-47B8-9A99-37E76FB78A1F Q37599664-6D0FF146-7BCC-402D-B2B4-5B058081804F Q37610628-F4539C5D-5100-4B29-8349-32002CAC76BD Q37672682-E6869D79-CF80-486E-9E68-B0F54100C0F6 Q37775427-17005D02-0C17-45EA-AD51-056B7CF2657A Q37804900-91DB32F1-C632-4405-950B-E32F63EF1486 Q38074721-94847324-CA78-4FDD-A735-9EEAB6F13093 Q38180309-51E6E30F-4010-4FCC-B0C1-EE9FCC9D5FA1 Q38962280-CA22D8A0-0FDF-499E-A12B-18B1A6523458 Q39023017-5C4B2C94-AF8A-47B7-A565-8540FE64EA73 Q39365796-C7D449CA-28EC-40CB-85E2-1337820BAF97 Q39368829-76898FEF-1F4D-42EE-97CB-49C4396EA8D0 Q40068276-3A1194C2-24DB-423C-BF27-3B4CE1BA914E Q41889215-1CE78583-3AD0-4AB1-A04A-280E728A689D Q41970114-002D8983-D6AA-4BC8-B8CF-A360C231F0D9 Q45886138-576C5A7B-7F56-4532-AA7A-1602A8A2DDB1 Q55385227-5E5B1079-54FB-4128-84A0-32FDEE9F77A3

P2860

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

http://www.wikidata.org/entity/Q35157425

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@ast

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@en

type

label

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@ast

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@en

prefLabel

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@ast

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@en

P1433

Q35157425-922A79DA-E88B-4257-B12F-64AA6802C561

P1476

Q35157425-A591547D-1B25-476E-8F6B-4F727BCC69BA

P2093

Q35157425-00A78B46-C210-48F9-BF3C-A55823BBA359

Q35157425-144BBCB3-029B-4DEC-9FFE-9E17FCBCF0B4

Q35157425-40C86FE5-35C2-4F92-96F0-36908CD68CDA

Q35157425-78AFD9B4-8D44-4520-B1C0-28E33015FB15

Q35157425-B4C0BD8D-A016-447C-B008-1304B379B6B4

Q35157425-CC4170A1-5B43-4D0B-8069-BA834B995C4E

Q35157425-F75E8A1C-22AB-43F1-8B4B-531AB4BFC783

P2860

Q35157425-0DEE1BB3-E672-430B-888D-0CC1609B5E4E

Q35157425-10BCE3D5-6F6C-4129-82D7-718A9D28B6AD

Q35157425-1282DD62-6315-4BF3-99F4-F115D1AB3095

Q35157425-209FE864-D711-4796-A0C8-F64B21302332

Q35157425-2E1775A6-385B-4183-A747-06B156C4222E

Q35157425-2FDACA47-50C9-4466-9F3B-F35F89838BDA

Q35157425-38ABBB58-6D98-4BA8-B5AE-5CE9DFE046EA

Q35157425-4661392D-06F5-4C5A-A0FB-92C6938C2902

Q35157425-48CE0957-AFF3-41E9-A0AA-F4354AEDCEA4

Q35157425-4C78A7BC-A881-40EE-BF3C-C5888D54B4AB

P304

Q35157425-05E6E77C-BC9F-4B5C-9101-C6E4B4F47731

P31

Q35157425-4E68FC2E-B499-4BE4-ABAB-4AC670E73174

P356

Q35157425-0C391D4F-378A-4BE4-94A0-22DDD3AB9506

P433

Q35157425-CE9CC726-7404-4627-8394-5C96BACA979E

P478

Q35157425-9BAE72B0-F87A-4372-A866-F9CFFA8BB0C5

P577

Q35157425-249E3FAF-1F89-4408-8DE8-4061BDC2B5F8

P5875

Q35157425-4DB8E193-DAEE-4FF6-B3DF-0395A218D824

P698

Q35157425-E5397563-7349-43BD-9F59-2E9C638D39CB

P921

Q35157425-BF9CC637-1ECE-4E7F-A7D0-163655A7E2E6

P932

Q35157425-D29E1271-801F-481F-9935-D3532DDE07A1

P356

P1433

International Journal of Cancer

P1476

Anti-tumor activity of an anti ...... anced in immunocompetent mice.

@en

P2093

Ben K Seon

http://www.w3.org/2001/XMLSchema#string

Hilda Tsai

http://www.w3.org/2001/XMLSchema#string

Hirofumi Toi

http://www.w3.org/2001/XMLSchema#string

Ken Shiozaki

http://www.w3.org/2001/XMLSchema#string

Masanori Tsujie

http://www.w3.org/2001/XMLSchema#string

Shima Uneda

http://www.w3.org/2001/XMLSchema#string

Tomoko Tsujie

http://www.w3.org/2001/XMLSchema#string

P2860

Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells

Defective angiogenesis in mice lacking endoglin

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development

Angiogenesis as a therapeutic target

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.

Recruiting dendritic cells to improve antibody therapy of cancer

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Regulatory T cells in cancer.

P304

2266-2273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.23314

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5626497

http://www.w3.org/2001/XMLSchema#string

P698

18224682

http://www.w3.org/2001/XMLSchema#string

P921

P932

4352952

http://www.w3.org/2001/XMLSchema#string